See more : Fu Burg Industrial Co., Ltd. (8929.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Savara Inc. (SVRA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Savara Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Koninklijke KPN N.V. (KKPNF) Income Statement Analysis – Financial Results
- Eloxx Pharmaceuticals, Inc. (ELOX) Income Statement Analysis – Financial Results
- Migdal Insurance and Financial Holdings Ltd. (MGDL.TA) Income Statement Analysis – Financial Results
- Autoneum Holding AG (0QOB.L) Income Statement Analysis – Financial Results
- Gaumont SA (GAM.PA) Income Statement Analysis – Financial Results
Savara Inc. (SVRA)
About Savara Inc.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 257.00K | 0.00 | 0.00 | 0.00 | 400.00K | 54.00 | 1.55K | 0.00 | 0.00 | 0.00 | 488.96K | 300.00K | 500.00K | 500.00K | 0.00 | 496.06K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 44.26M | 167.00K | 367.00K | 35.04K | 1.01M | 526.00K | 363.00K | 0.00 | 146.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -44.26M | -167.00K | -367.00K | 221.96K | -1.01M | -526.00K | -363.00K | 400.00K | -145.95K | 1.55K | 0.00 | 0.00 | 0.00 | 488.96K | 300.00K | 500.00K | 500.00K | 0.00 | 496.06K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 86.37% | 0.00% | 0.00% | 0.00% | 100.00% | -270,270.37% | 100.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 44.26M | 27.88M | 28.99M | 35.04M | 38.78M | 37.17M | 18.51M | 8.18M | 28.26M | 19.44M | 12.90M | 8.09M | 5.76M | 3.69M | 6.51M | 17.92M | 15.93M | 12.00M | 8.68M | 2.74M | 749.00K | 282.97K | 946.42K | 1.02M |
| General & Administrative | 15.67M | 10.93M | 12.35M | 14.26M | 13.08M | 10.65M | 11.08M | 2.82M | 10.96M | 9.49M | 8.52M | 7.52M | 7.60M | 5.32M | 5.00M | 9.72M | 8.68M | 7.24M | 4.90M | 4.02M | 1.59M | 1.39M | 2.04M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -410.98K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.67M | 10.93M | 12.35M | 14.26M | 13.08M | 10.65M | 11.08M | 2.82M | 10.96M | 9.49M | 8.52M | 7.52M | 7.19M | 5.32M | 5.00M | 9.72M | 8.68M | 7.24M | 4.90M | 4.02M | 1.59M | 1.39M | 2.04M | 793.97K |
| Other Expenses | -44.19M | -765.00K | -708.00K | -638.00K | 311.00K | 526.00K | 363.00K | -43.00K | 4.00K | 508.00K | -1.35K | -5.05K | 37.57K | 19.82K | 79.73K | 168.04K | 197.78K | 176.69K | 115.55K | 41.31K | 8.97K | 428.11K | 7.67M | 0.00 |
| Operating Expenses | 15.75M | 38.04M | 40.63M | 48.66M | 52.17M | 48.35M | 29.96M | 11.35M | 39.37M | 29.01M | 21.46M | 15.70M | 13.40M | 9.03M | 11.59M | 27.81M | 24.81M | 19.41M | 13.70M | 6.80M | 2.34M | 2.10M | 10.66M | 3.72M |
| Cost & Expenses | 60.01M | 38.04M | 40.63M | 48.66M | 52.17M | 48.35M | 29.96M | 11.35M | 39.37M | 29.01M | 21.46M | 15.70M | 13.40M | 9.03M | 11.59M | 27.81M | 24.81M | 19.41M | 13.70M | 6.80M | 2.34M | 2.10M | 10.66M | 3.72M |
| Interest Income | 4.44M | 88.00 | 2.28K | 1.48K | 0.00 | 0.00 | 0.00 | 122.00K | 130.00K | 69.00K | 60.27K | 73.56K | 76.59K | 92.87K | 7.16K | 549.96K | 2.17M | 1.16M | 496.06K | 103.04K | 9.27K | 1.27K | 31.69K | 40.92K |
| Interest Expense | 0.00 | 88.00K | 2.28M | 1.48M | 70.00K | 11.00K | 1.16M | 468.00K | 603.00K | 0.00 | 0.00 | 0.00 | 11.01K | 1.63K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.39K | 1.39K | 53.70K | 12.02K | 23.50K |
| Depreciation & Amortization | 175.00K | 167.00K | 367.00K | 693.00K | 1.01M | 526.00K | 363.00K | 346.00K | 146.00K | 85.00K | 39.52K | 90.05K | 38.00K | 19.82K | 79.73K | 168.04K | 197.78K | 176.69K | 115.55K | 41.31K | 8.97K | 428.11K | 7.67M | 1.91M |
| EBITDA | -59.13M | -37.90M | -40.37M | -47.44M | -77.09M | -69.50M | -31.91M | -10.48M | -39.09M | -28.62M | -21.44M | -15.47M | -13.22M | -8.43M | -11.21M | -27.14M | -24.11M | -29.16M | -13.09M | -6.66M | -2.32M | -1.72M | 2.72M | -1.81M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -18,565.76% | 0.00% | 0.00% | 0.00% | -2,650.50% | -72,642,592.59% | -1,850,904.39% | 0.00% | 0.00% | 0.00% | -1,741.95% | -3,719.81% | -5,318.37% | -4,822.65% | 0.00% | -303.95% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -60.01M | -38.84M | -41.48M | -49.30M | -79.03M | -70.05M | -29.96M | -10.95M | -39.37M | -29.28M | -21.54M | -15.63M | -13.40M | -8.54M | -11.29M | -27.31M | -24.31M | -29.84M | -13.20M | -6.80M | -2.34M | -2.10M | -10.66M | -3.72M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -19,182.88% | 0.00% | 0.00% | 0.00% | -2,737.00% | -72,912,962.96% | -1,891,408.27% | 0.00% | 0.00% | 0.00% | -1,746.51% | -3,761.90% | -5,461.97% | -4,862.21% | 0.00% | -2,661.58% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 5.31M | 689.00K | -1.54M | -315.00K | 852.00K | 18.00K | -3.48M | -332.00K | -469.00K | 577.00K | 58.92K | 68.51K | -273.93K | 88.78K | -39.37K | 662.34K | 2.17M | 504.69K | -11.58M | 103.04K | 11.49K | 45.79K | -5.70M | 0.00 |
| Income Before Tax | -54.70M | -38.15M | -43.01M | -49.62M | -78.17M | -70.03M | -33.43M | -11.28M | -39.84M | -28.70M | -21.48M | -15.56M | -13.26M | -8.45M | -11.33M | -26.65M | -22.14M | 29.33M | -24.78M | -2.33M | -2.33M | -2.05M | -16.36M | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -19,305.45% | 0.00% | 0.00% | 0.00% | -2,820.00% | -73,781,481.48% | -1,854,134.37% | 0.00% | 0.00% | 0.00% | -1,728.35% | -3,775.02% | -5,329.50% | -4,428.41% | 0.00% | -4,995.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 796.00K | 2.28M | 1.48M | 26.85M | -8.51M | -3.63M | -357.00K | 473.00K | -306.00K | -1.35K | -5.05K | -65.62K | -88.78K | 39.37K | 0.00 | 0.00 | 9.92M | 11.58M | 4.37M | -11.49K | 6.63K | 5.68M | -17.43K |
| Net Income | -54.70M | -38.95M | -45.30M | -51.10M | -105.03M | -61.52M | -29.80M | -10.92M | -39.84M | -28.70M | -21.48M | -15.56M | -13.26M | -8.45M | -11.33M | -26.65M | -22.14M | -29.33M | -24.78M | -6.70M | -2.33M | -2.11M | -16.34M | -3.70M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -19,882.10% | 0.00% | 0.00% | 0.00% | -2,730.75% | -73,781,481.48% | -1,854,134.37% | 0.00% | 0.00% | 0.00% | -1,728.35% | -3,775.02% | -5,329.50% | -4,428.41% | 0.00% | -4,995.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.33 | -0.25 | -0.34 | -0.86 | -2.62 | -1.85 | -1.70 | -3.27 | -17.19 | -16.41 | -19.63 | -22.86 | -32.94 | -44.88 | -169.85 | -516.69 | -430.96 | -693.77 | -724.89 | -231.21 | -120.54 | -235.41 | -1.96K | -769.94 |
| EPS Diluted | -0.33 | -0.25 | -0.34 | -0.86 | -2.62 | -1.85 | -1.70 | -3.27 | -17.19 | -16.41 | -19.63 | -22.86 | -32.94 | -44.88 | -169.85 | -516.69 | -430.96 | -693.77 | -724.89 | -231.21 | -120.54 | -235.41 | -1.96K | -769.94 |
| Weighted Avg Shares Out | 165.20M | 152.77M | 133.92M | 59.31M | 40.03M | 33.30M | 17.52M | 3.35M | 2.32M | 1.75M | 1.09M | 680.60K | 402.51K | 188.30K | 66.68K | 51.57K | 51.38K | 42.28K | 34.19K | 28.98K | 19.35K | 8.95K | 8.34K | 4.81K |
| Weighted Avg Shares Out (Dil) | 165.20M | 152.77M | 133.92M | 59.31M | 40.03M | 33.30M | 17.52M | 3.35M | 2.32M | 1.75M | 1.09M | 680.60K | 402.51K | 188.30K | 66.68K | 51.57K | 51.38K | 42.28K | 34.19K | 28.98K | 19.35K | 8.95K | 8.34K | 4.81K |
Savara to Present at the Citizens JMP Life Sciences Conference
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Citizens JMP Life Science Conference on May 14, 2024 at...
Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two abstracts for poster presentation at the American Thoracic Society (ATS) 2024 International Conference, taking place May...
Savara Announces New Employment Inducement Grant
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees. On March 21, 2024, Savara's Board of Directors granted the inducement awards to...
Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending December 31, 2023 and provided a business update. “We look forward...
Savara to Present at the Barclays 26th Annual Global Healthcare Conference
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference on March 14, 2024...
Savara Announces New Employment Inducement Grant
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On January 31, 2024, the Compensation Committee of Savara's Board of Directors granted...
3 stocks to turn $100 into $1,000 in 2024
The previous year was prosperous for many investors, resulting in significant gains in the stock market. The outlook for 2024 seems promising, especially in the technology sector.
Savara to Present at Two Upcoming Healthcare Conferences
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will be participating at the following investor healthcare conferences: Guggenheim 6th Annual Biotechnology Conference February 7, 2024 at...
Savara Introduces aPAP ClearPath™, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, recently launched aPAP ClearPath™, a new serum-based blood test that can be used by physicians in the U.S. to obtain a definitive...
Savara Added to the NASDAQ Biotechnology Index
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the company was added to the NASDAQ Biotech Index (Nasdaq: NBI), effective prior to market open on Monday, December 18, 2023....
Source: https://incomestatements.info
Category: Stock Reports